Hoth Therapeutics(US:HOTH) Prnewswireยท2025-09-16 12:14Core Insights - Hoth Therapeutics, Inc. is experiencing significant momentum across its clinical programs and corporate strategy, marking the strongest position in its history [1][3] Group 1: Clinical Developments - HT-001 is advancing globally with a Clinical Trial Application submitted to the European Medicines Agency (EMA) for a Phase II trial, with European patient enrollment expected to begin in early 2026 [6] - HT-KIT has successfully completed the Good Laboratory Practice (GLP) bioanalytical phase, exceeding regulatory thresholds, and is moving towards toxicology studies and regulatory submission [6] - The VA obesity program is focused on innovative approaches to address obesity in the veteran population, highlighting the company's commitment to tackling significant health challenges [6] Group 2: Financial Strategy - The Board of Directors has approved the expansion of Hoth's treasury reserve strategy to include Bitcoin, Ethereum, and Solana, allowing for potential purchases of up to $1 million in these digital assets [6] - This strategy reflects management's confidence in digital assets as a long-term store of value and a diversification strategy for the balance sheet [6] Group 3: Technological Integration - The adoption of Lantern Pharma's PredictBBB.ai platform, which achieves approximately 94% predictive accuracy for blood-brain barrier permeability, is facilitating faster, data-driven decision-making across Hoth's programs [6]